Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 21.76% is in line with its 5-year average of 21.96%, near the high end of its 5-year range (-5.99%–26.77%).
As of the fiscal period ended Tuesday, June 30, 2026. 0.97% above its 12-month average of 21.55%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
RETURN ON EQUITY (ROE)
21.76%
RETURN ON EQUITY (ROE) AVG TTM
21.55%
RETURN ON EQUITY (ROE) AVG 3Y
13.62%
RETURN ON EQUITY (ROE) AVG 5Y
21.96%
RETURN ON EQUITY (ROE) AVG 10Y
19.25%
RETURN ON EQUITY (ROE) AVG 15Y
1.26%
RETURN ON EQUITY (ROE) AVG 20Y
-25.38%
CURRENT VS TTM AVG
+0.97%
CURRENT VS 3Y AVG
+59.68%
CURRENT VS 5Y AVG
-0.92%
CURRENT VS 10Y AVG
+13.04%
CURRENT VS 15Y AVG
+1620.82%
CURRENT VS 20Y AVG
+185.72%
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
+67.23%
vs the sector median at left
Vertex Pharmaceuticals Incorporated
Market Cap
$134.24B
Return on Equity (ROE)
21.76%
TTM Avg
21.55%
3Y Avg
13.62%
5Y Avg
21.96%
Market Cap
$132.14B
Return on Equity (ROE)
41.59%
TTM Avg
-8.30%
3Y Avg
7.76%
5Y Avg
4.45%
Market Cap
$144.25B
Return on Equity (ROE)
7.61%
TTM Avg
7.38%
3Y Avg
9.51%
5Y Avg
10.24%
Market Cap
$123.70B
Return on Equity (ROE)
17.28%
TTM Avg
15.07%
3Y Avg
13.91%
5Y Avg
13.46%
Market Cap
$122.58B
Return on Equity (ROE)
6.16%
TTM Avg
4.23%
3Y Avg
6.35%
5Y Avg
7.74%
Market Cap
$118.26B
Return on Equity (ROE)
10.41%
TTM Avg
9.71%
3Y Avg
8.51%
5Y Avg
8.44%
Market Cap
$158.39B
Return on Equity (ROE)
5.09%
TTM Avg
9.04%
3Y Avg
13.32%
5Y Avg
16.07%
Market Cap
$105.97B
Return on Equity (ROE)
15.55%
TTM Avg
14.50%
3Y Avg
15.05%
5Y Avg
14.30%
Market Cap
$104.10B
Return on Equity (ROE)
N/A
TTM Avg
-189.06%
3Y Avg
-180.53%
5Y Avg
3473.86%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated (VRTX) | $134.24B | 21.76% | 21.55% | 13.62% | 21.96% |
| Bristol-Myers Squibb Company (BMY)vs › | $132.14B | 41.59% | -8.30% | 7.76% | 4.45% |
| Danaher Corporation (DHR)vs › | $144.25B | 7.61% | 7.38% | 9.51% | 10.24% |
| Intuitive Surgical, Inc. (ISRG)vs › | $123.70B | 17.28% | 15.07% | 13.91% | 13.46% |
| CVS Health Corp. (CVS)vs › | $122.58B | 6.16% | 4.23% | 6.35% | 7.74% |
| Medtronic plc (MDT)vs › | $118.26B | 10.41% | 9.71% | 8.51% | 8.44% |
| Pfizer Inc. (PFE)vs › | $158.39B | 5.09% | 9.04% | 13.32% | 16.07% |
| Stryker Corporation (SYK)vs › | $105.97B | 15.55% | 14.50% | 15.05% | 14.30% |
| McKesson Corporation (MCK)vs › | $104.10B | N/A | -189.06% | -180.53% | 3473.86% |
| Sanofi (SNY)vs › | $103.62B | 5.82% | 9.06% | 9.15% | 10.86% |
ROE
21.8%
ROA
16.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 21.76% |
| 2026-03-31 | 22.41% |
| 2025-12-31 | 21.18% |
| 2025-09-30 | 21.22% |
| 2025-06-30 | 21.18% |
| 2025-03-31 | -5.99% |
| 2024-12-31 | -3.26% |
| 2024-09-30 | -3.07% |
| 2024-06-30 | -3.32% |
| 2024-03-31 | 21.67% |
| 2023-12-31 | 20.59% |
| 2023-09-30 | 21.01% |
| 2023-06-30 | 21.75% |
| 2023-03-31 | 22.59% |
| 2022-12-31 | 23.88% |
| 2022-09-30 | 25.12% |
| 2022-06-30 | 26.77% |
| 2022-03-31 | 22.47% |
| 2021-12-31 | 23.19% |
| 2021-09-30 | 22.83% |
| 2021-06-30 | 21.66% |
| 2021-03-31 | 30.76% |
| 2020-12-31 | 31.22% |
| 2020-09-30 | 33.08% |
| 2020-06-30 | 27.67% |
| 2020-03-31 | 23.38% |
| 2019-12-31 | 19.34% |
| 2019-09-30 | 40.81% |
| 2019-06-30 | 43.70% |
| 2019-03-31 | 45.63% |
| 2018-12-31 | 47.28% |
| 2018-09-30 | 22.27% |
| 2018-06-30 | 15.46% |
| 2018-03-31 | 9.41% |
| 2017-12-31 | 12.99% |
| 2017-09-30 | 10.93% |
| 2017-06-30 | 15.37% |
| 2017-03-31 | 11.62% |
| 2016-12-31 | -9.95% |
| 2016-09-30 | -21.88% |
| 2016-06-30 | -28.21% |
| 2016-03-31 | -41.91% |
| 2015-12-31 | -59.38% |
| 2015-09-30 | -71.49% |
| 2015-06-30 | -82.03% |
| 2015-03-31 | -72.17% |
| 2014-12-31 | -68.70% |
| 2014-09-30 | -44.78% |
| 2014-06-30 | -40.24% |
| 2014-03-31 | -30.02% |
| 2013-12-31 | -32.81% |
| 2013-09-30 | -44.70% |
| 2013-06-30 | -37.72% |
| 2013-03-31 | -67.90% |
| 2012-12-31 | -10.71% |
| 2012-09-30 | 12.43% |
| 2012-06-30 | 39.16% |
| 2012-03-31 | 31.95% |
| 2011-12-31 | 3.76% |
| 2011-09-30 | -53.37% |
| 2011-06-30 | -240.45% |
| 2011-03-31 | -195.43% |
| 2010-12-31 | -149.74% |
| 2010-09-30 | -112.73% |
| 2010-06-30 | -81.42% |
| 2010-03-31 | -65.09% |
| 2009-12-31 | -58.57% |
| 2009-09-30 | -102.81% |
| 2009-06-30 | -83.17% |
| 2009-03-31 | -74.47% |
| 2008-12-31 | -192.51% |
| 2008-09-30 | -115.26% |
| 2008-06-30 | -158.49% |
| 2008-03-31 | -133.67% |
| 2007-12-31 | -144.23% |
| 2007-09-30 | -100.25% |
| 2007-06-30 | -66.97% |
| 2007-03-31 | -47.38% |
| 2006-12-31 | -40.89% |
| 2006-09-30 | -42.87% |
| 2006-06-30 | -140.26% |
| 2006-03-31 | -89.64% |
| 2005-12-31 | -85.05% |
| 2005-09-30 | -156.07% |
| 2005-06-30 | -136.02% |
| 2004-12-31 | -469.08% |
| 2004-09-30 | -221.35% |
| 2004-06-30 | -192.36% |
| 2004-03-31 | -136.02% |
| 2003-12-31 | -79.15% |
| 2003-09-30 | -62.13% |
| 2003-06-30 | -28.94% |
